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Introduction
Innate lymphoid cells (ILCs), a family composed of three functionally distinct subsets, are increasingly appreciated to play important roles in immunity, inflammation, and tissue remodeling as well as in the pathogenesis of inflammatory, allergic and autoimmune disorders (Hazenberg and Spits, 2014; Sonnenberg and Artis, 2015) . Lymphoid tissue-inducer (LTi) cells, a subpopulation of group 3 ILCs (ILC3), are implicated in the formation of tertiary lymphoid follicles -structures of accumulated lymphoid cells that arise in chronically inflamed adult tissue (Grogan and Ouyang, 2012) . In multiple sclerosis (MS), lymphoid aggregates have been found at autopsy within the inflamed meninges of a substantial portion of patients (Howell et al., 2011; Magliozzi et al., 2007; Serafini et al., 2004) . One mechanism that has been suggested for the genesis of these lymphoid aggregates is that LTi-like ILC3s, found in the cerebrospinal fluid, initiate and sustain formation of these focal aggregates in the setting of MS (Perry et al., 2012) . Recently daclizumab, a humanized monoclonal antibody against CD25, has been reported to reduce LTi cells in the circulation and cerebrospinal fluid of MS patients (Lin et al., 2015; Perry et al., 2012) . Given the expression of CD25 by other ILC subsets, ILC2s in particular (Monticelli et al., 2011; Sonnenberg et al., 2013) , and the focus exclusively on ILC3s in the previous studies, we sought to extend these reports by analyzing circulating ILCs in a cohort of relapsing remitting MS (RRMS) patients pre-and post-treatment with Daclizumab High Yield Process (DAC HYP) using a FACS panel capable of identifying ILC populations based on current consensus definitions.
Methods

PBMC samples
PBMC samples were collected in the SELECT clinical trial of DAC HYP, a form of daclizumab developed for subcutaneous administration (Gold et al., 2013) . SELECT is registered at ClinicalTrials.gov (Identifier NCT00390221). Whole blood samples were collected in CPT with sodium heparin tubes (BD Biosciences, San Jose, CA), shipped at ambient temperature without centrifugation to a central processing site where PBMC isolation and cryopreservation were performed within 24-48 h of collection.
Statistical analysis
For comparison of repeated measurements within two identical groups of patients, a paired Student's independent sample t-test was performed (GraphPad Prism, San Diego, CA). A p value b 0.05 was considered significant.
Results
NK cell/ILC FACS panel validation
A 16-color FACS panel was designed to identify NK cell and ILC subpopulations (Sup Fig. 1 ). Both fresh (n = 10) and frozen (n = 13) PBMC from healthy donors were used to extensively validate the panel.
Three Fig. 1 ) (Sonnenberg et al., 2013; Spits et al., 2013) . Preliminary analysis revealed that RORγt staining was lost or degraded in frozen PBMC samples from the SELECT study, possibly due to differences in handling or cryopreservation. Because all human ILC3 subsets, unlike the murine equivalents, uniformly express CCR6 (Cupedo et al., 2009; Sonnenberg et al., 2013) , and we observed a strong correlation between CCR6 and RORγt in freshly isolated healthy donor PBMC (Sup Fig. 3 and data not shown), CCR6 expression was used to define ILC3s in the T-bet − GATA-3 − gate in frozen PBMC samples from the SELECT study (Fig 2 and Fig. 4 ). Enhanced expression of CD25, CD127, and CD161 was observed on ILC2s relative to the other ILC subsets (Sup Fig. 4 ).
NK cell analysis
Paired patient PBMC samples from baseline (pre-treatment) and week 24 (post-treatment) from 10 placebo-treated and 20 DAC HYPtreated RRMS patients in the SELECT trial were analyzed. CD56 while the CD56 dim NK cells remained unchanged ( Fig. 1A and B) . Increased percentages and absolute numbers of CD56 trans NK cells were observed in DAC HYP-treated RRMS patients (p b 0.0001). The expression of T-bet, eomes and GATA-3 on each NK cell subset did not change with DAC HYP treatment (data not shown). These results were confirmed in a second cohort of PBMC samples from 10 placebo-treated and 20 DAC HYP-treated patients in the SELECT trial (data not shown).
ILC analysis
No significant differences were observed in the percentage or absolute number of total ILCs, or of ILC1s, ILC2s, or ILC3s specifically ( Fig. 2A-E) . A trend towards decreased percentages of ILC3s was observed following treatment with DAC HYP (Fig. 2C) ; however, this did not achieve statistical significance (p = 0.1105). Similar results were observed in a second cohort of PBMC samples from 10 placebo-treated and 20 DAC HYP-treated patients in the SELECT trial (data not shown). Little to no effects of treatment were observed on the expression of transcription factors (T-Bet, eomes, GATA-3) or cell surface proteins (CD7, CD11c CD127, and CD161) on any ILC subset following DAC HYP treatment (data not shown). Consistent with the effects of DAC HYP on other CD25-expressing cell populations, CD25 mean fluorescent intensity (MFI) was significantly decreased on ILC2s following treatment with DAC HYP (p = 0.005) (Sup Fig. 5 ).
Discussion
The 16-color FACS panel reported here simultaneously quantifies major NK cell and ILC subsets. Reproducing previously published results (Bielekova et al., 2006; Martin et al., 2010) (Freud et al., 2014) , but rather differentially regulated, and mature, NK cell subsets. Two previous publications have addressed the effects of DAC HYP therapy on ILCs. While both reports showed a reduction in total circulating ILCs (Perry et al., 2012; Lin et al., 2015) , in contrast to Perry et al., 2012 , Lin and colleagues did not observe statistically significant alterations in circulating LTi-like cells (a subpopulation of ILC3s) in response to DAC HYP treatment (Lin et al., 2015) . However, Lin et al. did report decreased LTi-like cells in the cerebral spinal fluid (CSF) of DAC HYP treated patients (Lin et al., 2015) . Like Lin et al., we did not observe significant alterations in the percentage or absolute numbers of circulating ILC3s, including LTi-like cells, as a result of DAC HYP therapy. While all of the studies are consistent on the effects of DAC HYP on NK cell subsets, there remains some question as to the effects on ILCs. Therefore, it is important to note differences between these studies. The Perry et al. and Lin et al. studies, using . Of particular significance for the studies detailed here, there is clear consensus in the ILC field that CD127 expression is a cardinal feature of not only LTi cells (Cupedo et al., 2009; Eberl and Littman, 2003; Mebius et al., 2001; Mebius et al., 1997) , but all ILC subsets (Hazenberg and Spits, 2014; Sonnenberg et al., 2013; Spits et al., 2013 Based on the broader and more detailed analysis of ILC subsets in DAC HYP-treated RRMS patients performed in these studies, we are able to confirm that DAC HYP treatment does not appear to have any significant effects on any of the circulating ILC subsets, including LTi-like ILC3s. One significant advantage of the current study is the inclusion of a placebo-treated patient population, which allowed the identification of potential changes in the ILC populations in RRMS patients over the 24-week study period. We observed no significant changes in total ILCs or in the three major subsets of ILCs in response to DAC HYP therapy, although we observed a trend towards increased absolute number of total ILCs between baseline and week 24; this increase did not achieve statistical significance (p = 0.1113) (Fig. 2B) . The lack of effect on mature ILCs was perhaps most striking when we analyzed the ILC2 population, which expresses CD25 (Monticelli et al., 2011; Sonnenberg et al., 2013) . While several murine studies have demonstrated that IL-2 promotes proliferation/survival and can enhance Th2 cytokine production from ILC2s (Moro et al., 2010; Roediger et al., 2015) , Neill, et al. reported that IL-2 was neither sufficient nor required for ILC2 proliferation in vitro (Neill et al., 2010) . Further, no study to date has addressed the importance of endogenous IL-2 in ILC2 development and function in vivo. Our own data in human patients demonstrate that despite decreased expression of CD25 on ILC2s, ILC2 numbers and frequencies were not changed in MS patients treated with DAC HYP. These data suggest that CD25-dependent IL-2 signaling does not play a major role in the development or maintenance of ILC2s, in contrast to the role of IL-2 in NK and regulatory T cell biology.
Taken together, the data herein demonstrate that DAC HYP has a significant impact on circulating NK cell populations but does not alter the number or composition of circulating innate lymphoid cell populations.
